Bullish
Kairos Pharma Highlights CL-741 Acquisition and 2026 Clinical Milestones
Kairos Pharma Ltd. has announced plans to expand its oncology pipeline in 2026, including the acquisition of global rights to CL-741, a Phase 1-ready ...